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Purpose: To evaluate the midterm efficacy and safety of the iStent® glaucoma device in patients 
with secondary open-angle glaucoma.
Patients and methods: A prospective, nonrandomized, interventional case series involving 
10 patients with secondary open-angle glaucoma (traumatic, steroid, pseudoexfoliative, and 
pigmentary glaucoma) of recent onset who underwent ab interno implantation iStent. Patients 
were assessed following the procedure on days 1, 7, and 15 and months 1, 3, 6, and 12, and 
examinations included visual acuity, intraocular pressure (IOP) measurement using Goldmann 
tonometry, number of glaucoma medications, and complications. Wilcoxon rank-test for data 
with abnormal distribution was used for the analysis of IOP and glaucoma medications at 
baseline versus 3, 6, and 12 months following the procedure.
Results: The mean baseline IOP was 26.5 ± 7.9 (range 18–40) mmHg, and significantly 
decreased in 10.4 ± 9.2 mmHg at three months (P , 0.05), in 7.4 ± 4.9 mmHg at six months 
(P , 0.05), and in 6.6 ± 5.4 mmHg at 12 months (P , 0.05) following iStent implantation. The 
mean number of hypotensive medications at baseline was 2.9 ± 0.7 (range 2–4). Statistically 
significant reductions in the number of medications of 1.1 ± 1.1 were observed at three months 
(P , 0.05), 1.0 ± 0.7 at six months (P , 0.05), and 1.1 ± 0.6 at 12 months (P , 0.05). No 
significant changes in visual acuity were noted. The most common complications comprised 
mild hyphema in seven eyes and transient IOP $30 mmHg in three eyes on postoperative day 1. 
Obstruction of the lumen of the stent with a blood clot was seen in three eyes, and all instances 
resolved spontaneously.
Conclusion: The iStent is a safe and effective treatment option in patients with secondary open-
angle glaucoma, and reduces the topical treatment burden in one hypotensive medication.
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Introduction
In primary open-angle glaucoma, the site that offers greater resistance to outflow in 
the aqueous humor circulation is the juxtacanalicular meshwork. In the pseudoexfolia-
tion syndrome,1,2 pigment dispersion syndrome,3,4 post-traumatic angle recession,5–7 
or chronic treatment with steroids,8–10 this resistance may appear at different levels, 
such as pretrabecular or trabecular, leading to increased intraocular pressure (IOP) and 
thus to the optic neuropathy known as secondary open-angle glaucoma. Bypassing this 
point of greatest resistance would restore the outflow and regulate IOP.
The iStent® (Glaukos Corporation, Laguna Hills, CA) is a new titanium device 
designed to be placed within Schlemm’s canal, which connects directly to the anterior 
chamber. By means of bypassing the trabecular meshwork, this 60 µg weight stent with Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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a snorkel bore diameter of 120 µm facilitates the outflow of 
aqueous humor into the collector channels that carry it to the 
episcleral veins.11 Recent studies have shown that in primary 
open-angle glaucoma, the iStent controls the physiologic 
flow of aqueous humor through the conventional route and 
restores the IOP.12,13
The effectiveness of this new device depends on the 
permeability of the post-trabecular system (Schlemm’s canal 
and collector channels). Currently, there is no scanning tech-
nique available to assess the permeability of routes beyond 
the trabecular meshwork; therefore, we do not know a priori 
if implantation of a trabecular iStent is able to restore the 
aqueous humor drainage completely. However, clinically 
we have indirect signs of a well functioning post-trabecular 
system, such as blood reflux on gonioscopy with   three-mirror 
lens. When the pretrabecular injury is de novo, we assume 
that the other angle structures are unaffected with proper 
function. Based on this hypothesis, all patients with ocular 
hypertension or newly diagnosed glaucoma and previously 
normotensive, who presented with increased IOP induced 
by trabecular mechanism, either due to pseudoexfoliation 
material, pigment dispersion, use of steroids, or secondary 
trabecular injury after angular recession, were assumed to 
have normal post-trabecular permeability and were potential 
candidates for this surgical procedure.
The aim of this study was to evaluate the safety and effi-
cacy of the iStent in reducing IOP in patients with this type 
of secondary open-angle glaucoma.
Material and methods
This was a prospective, nonrandomized, noncompara-
tive, interventional case series. All subjects were patients 
from the Glaucoma Department of the Instituto Condal de 
  Oftalmologia, Barcelona. Prior to study enrollment, all par-
ticipants provided informed consent to participate in the study 
which adhered to the tenets of the Declaration of Helsinki.
The study involved 10 eyes of 10 patients with secondary 
open-angle glaucoma (traumatic, pseudoexfoliative, steroid, 
or pigmentary glaucoma) of recent onset, ie, less than three 
months. Other inclusion criteria were an IOP $18 mmHg 
(in at least two consecutive consultations) as suggested in 
previous studies,14–16 current use of at least one glaucoma 
medication, a visible scleral spur with gonioscopy, and 
readiness and willingness to attend follow-up visits for at 
least one year. We excluded any type of glaucoma other 
than the ones already mentioned. Other exclusion criteria 
were presence of angle closure, history of any glaucoma 
surgery or cyclodestructive procedure, elevated episcleral 
venous pressure, cloudy cornea or corneal opacities likely 
to prevent the surgeon from achieving a clear gonioscopic 
view of the nasal angle, or peripheral anterior synechiae in 
the nasal angle.
Data collected from each subject before surgery included 
age, gender, affected eye, type of secondary glaucoma, 
concurrent eye diseases, visual acuity, IOP, and number 
of hypotensive medications. Follow-up examination were 
performed on days 1, 7, and 15 and at months 1, 3, 6, and 
12, and comprised visual acuity, slit lamp examination, 
gonioscopic evaluation of the location of the stent, IOP 
(Goldmann tonometry), number of hypotensive medications 
used, and complications.
No washout of hypotensive medications prior to surgery 
was required. Patients discontinued use of all glaucoma 
medications in the immediate postoperative period and were 
instructed to restart the treatment only if the investigator 
determined that additional lowering of IOP was needed.
surgical procedure
The iStent is a L-shaped titanium trabecular stent. Its long 
arm has a sharpened end, which allows drilling of the trabe-
cular meshwork into Schlemm’s canal (intraluminal portion). 
The shorter arm remains located in the anterior chamber 
(extraluminal portion). All surgeries were performed by one 
of the authors (SD). Topical anesthesia with 1% hydrochlo-
ride tetracaine, and 4% oxybuprocaine hydrochloride was 
used in all cases. After performing a 1.4 mm self-sealing 
temporal corneal incision, a viscoelastic agent (1% sodium 
hyaluronate) was injected to fill the anterior chamber. The 
nasal trabeculum was identified using a Swan-Jacobs gonio-
prism. Under gonioscopic view, the iStent attached at the end 
of a hand-piece applicator was introduced into the anterior 
chamber and positioned into the Schlemm’s channel. While 
performing this maneuver, blood reflux was sometimes 
observed, indicating that the stent was correctly positioned. 
The stent was easily released by pressing the button on 
the applicator, and the viscoelastic agent was removed by 
manual aspiration. In the early postoperative period, a fixed 
combination of tobramycin and dexamethasone eye drops 
(Tobradex®, Alcon Inc, Fort Worth, TX) were administered 
three times daily for two weeks. Hypotensive agents were 
administered as needed.
statistical analysis
Statistical analysis was performed with SPSS for Windows 
(SPSS Inc., Chicago, IL). Wilcoxon rank-test for data with 
abnormal distribution was used for the analysis of IOP and Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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number of glaucoma medications before surgery versus 
months 3, 6, and 12 after surgery. A P value less than 0.05 
was considered statistically significant.
Results
Ten iStents were implanted between October 10, 2005 and 
March 5, 2007. Five patients underwent ocular surgeries prior 
to iStent implantation (Table 1). The mean age was 54.4 ± 7.9 
years and 90% were male. Four eyes were diagnosed with 
traumatic glaucoma, four eyes with steroid glaucoma, one 
eye with pigmentary glaucoma, and one eye with pseudoex-
foliative glaucoma. Mean follow up was 12.7 ± 4.6 months. 
Of the 10 patients enrolled in the study, eight completed the 
12-month follow-up. One patient was excluded from the 
study because IOP was not controlled with maximum medica-
tion at six months and consequently required trabeculectomy. 
The second patient was lost after the three-month visit when 
he returned to his country of origin.
The average pre-iStent IOP was 26.5 ± 7.9 (range 
18–40) mmHg, and the stent effectively decreased the IOP 
over the following 12 months (Table 2 and Figure 1). Statistical 
analysis was performed at months 3, 6, and 12, taking into 
account the change in the number of patients, ie, n = 10 at 
three months, n = 9 at six months, and n = 8 at 12 months. At 
all three time points, a decrease in mean IOP was observed, 
resulting in 17.0 ± 2.5 mmHg at 12 months (Table 3).
This reduction in IOP was statistically significant after 
iStent implantation at three months (10.4 ± 9.2 mmHg, n = 10, 
P , 0.05), at six months (7.4 ± 4.9 mmHg, n = 9, P , 0.05), 
and at 12 months (6.6 ± 5.4 mmHg, n = 8, P , 0.05). The 
proportion of patients that achieved an IOP #18 mmHg was 
70% (n = 7) at three months, 77.7% (n = 7) at six months, 
and 75% (n = 6) at 12 months.
The average number of hypotensive medications pre-
iStent was 2.9 ± 0.7 and ranged from two to four medications. 
The mean number of hypotensive medications over time is 
illustrated in Figure 2. The study showed a significant reduc-
tion in the number of medications of 1.1 ± 1.1 (P , 0.05) 
at three months, 1.0 ± 0.7 (P , 0.05) at six months, and 
1.1 ± 0.6 (P , 0.05) at 12 months postoperatively.
After implantation of the iStent, an IOP of #18 mmHg 
was achieved by 12.5% (1/8) without use of hypotensive 
medications and by 87.5% (7/8) with at least one medica-
tion. At 12 months, 25% (2/8) needed at least two glaucoma 
medications.
Complications related to the surgical procedure included 
malposition of the iStent in one case that required a surgi-
cal repositioning which was successful. The most common 
postoperative complications were mild hyphema at 24 hours 
postprocedure (n = 7 or 70%), IOP $30 mmHg on postopera-
tive day 1 (n = 4 or 40%), that was medically controlled yet 
persisted in two eyes up to seven days, and corneal edema 
(n = 2 or 20%) which resolved without sequelae. Obstruction 
of the lumen of the stent with a blood clot was seen in three 
eyes (30%) which spontaneously resolved without the need 
for antifibrinolytic therapy. In this series of patients, there 
was no occlusion of the iStent due to the iris. In addition, no 
hypotony, choroidal detachment, temporary flattening of the 
anterior chamber, or endophthalmitis occurred. No significant 
changes were observed in visual acuity.
The patient who required trabeculectomy had had previ-
ous surgery for traumatic glaucoma with pars plana vitrec-
tomy and phacoemulsification.
Discussion
In all types of secondary glaucoma (due to pseudoexfoliation, 
pigment, trauma, or steroids), obstruction and consequent 
increased resistance to outflow of aqueous humor through 
the conventional route cause increases IOP. We believe that 
in patients with de novo increased IOP, who previously have 
Table 1 Demographics of the study population
Patient  Gender Age  Eye VA before surgery Type of secondary glaucoma Prior ocular surgery
1 M 43 OD 20/50 TG PPV
2 M 47 Os 20/200 TG –
3 M 56 Os 20/200 TG PPV, cataract surgery + iOL implantation
4 M 44 Os 20/200 sG –
5 F 62 OD 20/40 sG cataract surgery + iOL implantation
6 M 57 OD 20/25 sG –
7 M 50 OD 20/25 PG –
8 M 60 OD 20/20 sG PKP
9 M 66 Os 20/20 PeXG –
10 M 59 OD 20/800 TG PPV, cataract surgery + iOL implantation
Abbreviations: F, female; M, male; OD, right eye; Os, left eye; PeXG, pseudoexfoliative glaucoma; PG, pigmentary glaucoma; PKP, penetrating keratoplasty; PPV, pars plana 
vitrectomy; sG, steroid glaucoma; TG, traumatic glaucoma; VA, visual acuity; iOL, intraocular lens.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 2 intraocular pressure over time by patient
Patient  Before surgery Day 1 Day 7 Day 15 Month 1 Month 3 Month 6 Month 12
1 24 33 14 12 12 12 12 12
2 36 8 26 13 8 12 Lost to follow-up
3 40 8 19 12 22 20 28 Trabeculectomy
4 30 12 13 36 18 19 18 20
5 21 50 22 27 21 15 18 18
6 30 52 16 22 22 18 18 17
7 18 13 20 30 20 22 18 18
8 30 10 18 18 15 10 21 19
9 18 10 14 16 14 16 15 17
10 18 10 12 10 22 17 14 15
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Figure 1 Mean iOP at each study visit.
Abbreviation: iOP, intraocular pressure.
had normal IOP or recent history of glaucoma, the perme-
ability of Schlemm’s canal and collecting channels should 
be intact and function properly. Performing a bypass of the 
trabecular meshwork between the anterior chamber and 
Schlemm’s canal and restoring the physiologic aqueous 
humor outflow might be an effective treatment option in this 
type of glaucoma. Because there are currently no available 
tools to evaluate the permeability of the conventional route, 
it is very important to assess slit lamp findings carefully, 
looking for indirect signs of blood reflux into Schlemm’s 
canal using a goniolens or three mirror lens, as well as to take 
a thorough clinical history in order to determine the proper 
indication of iStent. Assuming that a well functioning iStent 
would increase the outflow of aqueous humor at the trabecular 
level, the percentage of IOP reduction would theoretically be 
higher in hypertensive than in normotensive eyes.13
The effectiveness of the iStent may depend on or be 
related to the permeability of the drainage system beyond 
Schlemm’s canal. However, the long-term effectiveness of 
any device that bypasses the trabecular meshwork depends on 
scarring around the intraluminal portion of the iStent, which 
may be a limiting factor in aqueous humor flow through 
the stent.11 Theoretic models show that increased flow 
through the trabecular bypass would lead to an expansion 
of Schlemm’s canal and collecting channels, which would 
further diminish the resistance to flow in eyes with glaucoma, 
from the anterior chamber into the aqueous veins.12
The existence of blockages at other levels beyond 
Schlemm’s canal may be one of the causes of failure of 
this surgical procedure. Therefore, being able to predict the 
status of these drainage pathways is essential to prognosti-
cate the future effectiveness of the iStent. Several studies 
have shown that, by bypassing the trabecular meshwork, 
the IOP decreases steadily in patients with chronic open-
angle glaucoma when the iStent is implanted concomi-
tantly with phacoemulsification. Spiegel et al14,15 reported 
decreases in IOP of 25% (5.7 ± 3.8 mmHg) in 47 patients with 
an initial IOP of 21.5 ± 3.7 mmHg, and a reduction of 
0.5 ± 0.8 in the number of hypotensive medications per day 
to six months. Samuelson et al16 described a decrease in IOP 
of 18.3% (4.4 mmHg) with an initial IOP of 21.7 mmHg 
at 12 months in 42 patients and a reduction in the number Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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of medications per day of 1.2 ± 0.7. In a multicenter study, 
Samuelson et al17 compared the iStent with phacoemul-
sification   versus phacoemulsification alone. Preoperative 
IOPs were 18.4 ± 3.2 with hypotensive medications, and 
25.4 ± 3.6 without   medications (after a washout period). 
They found a decrease of .30% (8.4 ± 3.6 mmHg in the 
iStent with phacoemulsification group and 8.5 ± 4.3 mmHg 
in the phacoemulsification alone group). They also found a 
reduction in the number of medications of 1.4 ± 0.8 in the 
iStent with phacoemulsification group and 1.0 ± 0.8 in the 
phacoemulsification alone group.
In our series of patients with secondary open-angle glau-
coma, iStent insertion achieved IOP reductions of 28.6% 
(7.4 ± 4.9 mmHg) at six months in nine patients and 27.3% 
(6.6 ± 5.4 mmHg) at 12 months in eight patients without 
associated cataract surgery. These percentage values of IOP 
lowering are superior to those reported in previous studies14–16 
and are similar to the multicenter study of Samuelson et al17 
where they compared preoperative IOP without medications. 
This is probably due to the fact that pretreatment IOP values 
were greater in our series, with similar absolute values of 
lowering compared with the other studies mentioned ear-
lier, taking into account that the preoperative IOP was with 
hypotensive medications. This finding supports the hypoth-
esis that the success of the iStent is greater with increased 
preoperative IOP.13
The reduction in the number of hypotensive medications 
in our series was 1.0 ± 0.7 at six months and 1.3 ± 0.6 at 
12 months, which are values similar to the series published 
by Samuelson et al16,17 and higher than in the study conducted 
by Spiegel et al.15
Our study shows that the insertion of iStent is a safe 
procedure that does not have any of the more common com-
plications of filtering surgery. Furthermore, the conjunctiva 
remains intact, so that if a filtering procedure is needed 
later, the success rate should not be affected. The decrease 
in the number of medications is a positive factor to consider, 
because we have found that the implantation of one iStent 
reduces the topical treatment burden in one medication, 
making this type of surgery a good option in patients with 
intolerance to glaucoma eye drops. If we seek a greater 
reduction in the IOP, we should consider the implantation 
of more than one device.
For patients with pigmentary glaucoma or pseudoex-
foliation, we do not know if there is a direct passage of 
pigmentary material into Schlemm’s canal and collecting 
ducts. This consideration should be evaluated in future 
pathologic studies. The small number of patients is a limi-
tation of our study, so larger and longer-term studies are 
needed to confirm these results in patients with secondary 
open-angle glaucoma, considering also the placement of 
more than one iStent.
Table 3 Mean intraocular pressure at baseline and months 3, 6, and 12
Follow-up time Patients (n) Mean (±SD) IOP 
before surgery
Mean (±SD) IOP 
after surgery
P value 
(Wilcoxon rank-test)
3 months 10 26.3 ± 8.2 16.1 ± 3.9 0.016
6 months 9 25.2 ± 7.9 18.0 ± 4.6 0.011
12 months 8 23.4 ± 6.0 17.0 ± 2.5 0.018
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
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Figure 2 Mean number of hypotensive medications used at each study visit.Clinical Ophthalmology
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Presently, widespread use of intraocular   triamcinolone 
for macular pathology has led to a substantial increase in the 
incidence of steroid ocular hypertension, which sometimes 
cannot be managed with topical treatment. In these cases, 
an iStent might achieve prompt control of IOP with minimal 
invasive risk, and be extremely convenient and suitable for 
patients with retinal pathology.
Conclusion
This study shows that iStent implantation without concomi-
tant cataract surgery is a safe treatment option in patients 
with secondary open-angle glaucoma. The procedure is 
also effective because it achieves IOP reduction depending 
on the initial pressure and decreases the burden of topical 
glaucoma medication.
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